Multiple Sclerosis (Primary Progressive) | Emerging Therapies | Ocrevus (ocrelizumab) | Wave 3 | US | 2018

Market Overview

In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS). Although the drug’s efficacy appears more modest in this population than in patients with relapsing forms of MS, the combination of proven clinical benefits and a positive safety profile (to date) yields a highly compelling product for a deeply underserved population. Even so, questions remain about exactly how it will fit into the progressive MS treatment algorithm. DRG’s launch tracking series will examine how the perception and performance of Ocrevus has evolved through Year 1 with an MS prescriber base that has hitherto struggled to treat PP-MS.

QUESTIONS ANSWERED

What is the awareness of, familiarity with, and perception of Ocrevus among U.S. neurologists?
For which PP-MS patients are neurologists prescribing Ocrevus, what are the reasons for prescribing, and how satisfied are they with Ocrevus?
What promotional messages and activities are Genentech/Roche using to support the Ocrevus launch in PP-MS?
How does the trial and adoption of Ocrevus in PP-MS compare to the trial and adoption of Ocrevus and other recently launched products in the saturated relapsing MS market? How do adopters and nonadopters in PP-MS compare across key metrics?

PRODUCT DESCRIPTION

Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months post-commercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Markets covered: United States.

Primary research: Survey of approximately 75 U.S. neurologists.

Key metrics included:

Unaided and aided awareness of Ocrevus.
Familiarity with and impressions of Ocrevus.
Prescriber and nonprescriber profiles.
Willingness to prescribe Ocrevus.
Performance of Ocrevus on key attributes.
Sales representative frequency, reach, and satisfaction.
Benchmarking against previously launched MS agents.

Contact sales account_box

Report

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Hyperkalemia is a potentially life-threatening condition characterized by a serum potassium concentration that exceeds 5.5 mEq/L. Despite various guidelines, a universally accepted consensus on the…

north_east

Report

Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation and progressive damage to intrahepatic bile ducts, leading to bile buildup, followed by…

north_east

Report

Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…

north_east

Report

Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…

north_east

Report

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)

Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…

north_east

Product logins

Multiple Sclerosis (Primary Progressive) | Emerging Therapies | Ocrevus (ocrelizumab) | Wave 3 | US | 2018

Related Market Assessment Reports

Hyperkalemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hyperkalemia (US)

Primary Biliary Cholangitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Primary Biliary Cholangitis (US)

Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)

Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)

Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)

Follow us

Contact us